API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
TP-1287 is an investigational oral phosphate prodrug of the CDK9 inhibitor alvocidib. This prevents productive transcription and causes reduction of mRNA in genes (c-MYC and MCL-1) transcription leading in tumor cell apoptosis.
Lead Product(s): TP-1287
Therapeutic Area: Oncology Product Name: TP-1287
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2023
Details:
TP-1287 is enzymatically cleaved, yielding active moiety, potent inhibitor of CDK9. Inhibiting CDK9 is thought to downregulate transcription of target genes, including MCL-1, reducing leukemic blast viability in MCL-1–dependent hematologic malignancies.
Lead Product(s): TP-1287
Therapeutic Area: Oncology Product Name: TP-1287
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
These data, highlighting a novel biomarker detection method for CDK9 inhibition and evaluating the anti-tumor activity of alvocidib and TP-1287 in hematologic cancer cells, are being presented at the American Association for Cancer Research (AACR) Virtual Meeting II.
Lead Product(s): TP-1287
Therapeutic Area: Oncology Product Name: TP-1287
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
Preliminary findings from a Phase 1, first-in-human, dose escalation study of TP-1287 showed clinical activity and a tolerable safety profile as a monotherapy in patients with heavily pretreated, relapsed and refractory solid tumors.
Lead Product(s): TP-1287
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020